{"url_path":"/sec/cccc/8-k/2026-06-24/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1662579/0001628280-26-045194-index.html","accession_number":"0001628280-26-045194","cik":"0001662579","ticker":"CCCC","issuer_name":"C4 Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1662579/0001628280-26-045194-index.html","primary_entity_key":"0001662579","primary_entity_name":"C4 Therapeutics, Inc."},"word_count":364,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 24, 2026, C4 Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the four proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement on Schedule 14A, which was filed with the U.S. Securities and Exchange Commission on April 29, 2026. The final voting results are set forth below.\n\na) The stockholders of the Company elected each of Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors, to hold office until the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified or until his earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class III directors were as follows:\n\nFor\n\nWithheld\n\nBroker Non-Votes\n\nAndrew J. Hirsch\n\n47,797,964\n\n8,247,406\n\n21,049,125\n\nStephen Fawell, Ph.D.\n\n47,811,414\n\n8,233,956\n\n21,049,125\n\nUtpal Koppikar\n\n46,491,892\n\n9,553,478\n\n21,049,125\n\nb) The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company’s named executive officers. The results of the stockholders’ vote with respect to this proposal were as follows:\n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n54,935,574\n\n1,070,926\n\n38,870\n\n21,049,125\n\nc) The stockholders of the Company ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to this ratification proposal were as follows:\n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n76,891,210\n\n185,427\n\n17,858\n\n0\n\nd) The Company’s stockholders approved an amendment to the Company’s 2020 Stock Option and Incentive Plan to amend the evergreen provision to include any outstanding pre-funded warrants in the total number of shares of common stock that are issued and outstanding as of each December 31 for purposes of calculating the evergreen increase. The results of the stockholders’ vote with respect to this proposal were as follows:\n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n33,713,572\n\n22,287,787\n\n44,011\n\n21,049,125\n\nNo other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting."}